Posilac Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

Avoid prolonged or repeated contact with Posilac with eyes and skin. Posilac is a protein. Frequent skin contact with proteins may produce an allergic reaction in some people. Always wash hands and skin exposed to Posilac with soap and water after handling. Clothing soiled with the product should be laundered before reuse.

  • For use in animals only.
  • Keep this and all medications out of the reach of children.


  • Use in lactating dairy cattle only.
  • Safety to replacement bulls born in dairy cows injected with Posilac has not been established.
  • Avoid injecting within 2 weeks of slaughter to minimize injection site blemishes on carcass.
  • Nutritional Management: Cows injected with Posilac increase voluntary feed intake over several weeks following the start of supplementation. This increase occurs sooner for first lactation cows than for second lactation or older cows. The increased feed intake continues during supplementation and may continue through the dry period and the following early lactation. However, cows treated with Posilac tend to maintain lower body condition than untreated cows. This effect is more pronounced for second lactation or older cows.
    • Feed diets formulated to meet or exceed the nutritional requirements recommended by the National Research Council. Consider milk yield, stage of lactation, and body condition when making dietary changes. Manage the feeding program to optimize milk yield and to have cows in appropriate body condition, particularly during late lactation and the dry period. Increasing the energy density of diets fed to cows treated with Posilac is normally not required. Avoid sudden dietary changes.
  • Reproduction: Cows injected with Posilac may have reduced pregnancy rates and increased days open. Have a comprehensive and ongoing herd reproductive health program in place on your dairy before using Posilac.
  • Mastitis: Cows injected with Posilac are at an increased risk for mastitis (visibly abnormal milk) and may have higher somatic cell counts. Have comprehensive mastitis management practices in place on your dairy before using Posilac.
  • General Health: Cows injected with Posilac may require more therapeutic drug treatment for mastitis and other health problems. Cows injected with Posilac may experience periods of increased body temperature unrelated to illness. To minimize the effect, take appropriate measures during periods of high environmental temperature to reduce heat stress. Use care to differentiate whether increased body temperature is caused by illness or use of Posilac. Cows injected with Posilac may have more enlarged hocks and disorders of the foot region. Posilac treatment may reduce hemoglobin and hematocrit values.
  • Injection Site Reactions: A mild temporary swelling of 3-5 cm (1 -2 inches) in diameter may occur at the injection site beginning about 3 days after injection and may persist up to 6 weeks following injection. Larger swellings may occur in cows injected in the neck area compared to the behind the shoulder or in the depression on either side of the tailhead. Some cows may experience swellings up to 10cm (4 inches) in diameter that remain permanent but are not associated with animal health problems. However, if permanent blemishes are objectionable to you, stop supplementation of these cows. Also stop using Posilac in cows with injection site swellings that repeatedly open and drain.
  • Udder Edema: Posilac is approved for use starting during the 9th or 10th week of lactation. Risk of udder edema may increase if injections start later in lactation.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.


To increase production of marketable milk in healthy lactating dairy cows.


There is currently no drug history available for this drug.

Other Information

Sterile, prolonged-release injectable formulation of a recombinant DNA-derived bovine somatotropin analog in single-dose syringes each containing 500 mg of sometribove zinc.

Posilac Manufacturers

  • Elanco Animal Health Co
    Posilac (Sometribove) Suspension [Elanco Animal Health Co]

Login To Your Free Account